Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Solitary Fibrous Tumors 1Sarcoma 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1

Interventions

Oxaliplatin 2Leucovorin 2Gemcitabine 2Fluorouracil 2Bevacizumab 2Azacitidine 2temsirolimus 1ruxolitinib 1rucaparib 1repotrectinib 1fludarabine 1ceritinib 1cc-486 1abiraterone 1Uncertainty 1Thalidomide 1Temozolomide 1Suspensions 1Sorafenib 1Quality of Life 1Psychosocial Intervention 1Patient Reported Outcome Measures 1Paclitaxel 1Molecular Diagnostic Techniques 1Lenalidomide 1Irinotecan 1Interleukin-2 1Injections 1Immunotherapy 1INCB057643 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × Suspensions × Plasma cell × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡